Regentis Biomaterials Ltd.
RGNTStock
$2.22
Market Cap—
P/E—
Div yield—
Beta—
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-72.75%
Price vs S&P 500 (4W)-72.58%
VGM Score17.07
Industry Peers — Orthopedic & Prosthetic Devices(33)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RGNTRegentis Biomaterials Ltd. | — | — | F | $2.22 |
| ISRGIntuitive Surgical Inc. | D | B | D | $402.33 |
| EWEdwards Lifesciences Corp | D | C | B | $87.84 |
| STESTERIS plc | B | B | C | $221.13 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | C | $93.75 |
| ALGNAlign Technology Inc | C | C | C | $178.41 |
| SNNSmith & Nephew plc | B | C | C | $31.41 |
| MSAMine Safety Incorporated | C | C | C | $173.39 |
| ESTAEstablishment Labs Holdings Inc. | F | A | A | $92.30 |
| ENOVEnovis Corporation | B | D | C | $28.07 |
| CDRECadre Holdings, Inc. | B | C | D | $30.18 |
About
Regentis Biomaterials develops regenerative medicine solutions for orthopedic tissue repair. Its lead product, GelrinC, is a cell-free hydrogel implant designed to treat cartilage injuries in the knee, based on the company's proprietary Gelrin platform. The company targets the significant market opportunity in orthopedic regenerative medicine.